A pill that cuts off the supply of nutrients to tumors shows promise for treating people with the rare type of pancreatic cancer
“Doubled the length of time before their disease worsened” sounds great until you read that the article linked and excerpted below is talking about doubling 5.5 months to 11.4 months. My point is not that Sutent is a wonder drug for pancreatic cancer patients. My point is to draw your attention to therapy that “cuts off the supply of nutrients to tumors shows promise for treating people with the rare type of pancreatic cancer…”
According to the Wikipedia entry for Sutent, the mechanism of action is called anti-angiogenesis. Cutting of the nutrients to the tumor is another way of saying that Sutent is anti-angiogenic.
“Pancreatic neuroendocrine tumors– In November 2010, Sutent gained approval from the European Commission for the treatment of ‘unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression in adults’. In May 2011, the USFDA approved Sunitinib for treating patients with ‘progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic)’.“
A pill that cuts off the supply of nutrients to tumors shows promise for treating people with the rare type of pancreatic cancer that afflicted Apple CEO Steve Jobs.
In a study of 171 people with advanced pancreatic neuroendocrine tumors, the drug, Sutent, doubled the length of time before their disease worsened.
Cancer progressed in 5.5 months among patients on placebo vs. 11.4 months among patients on Sutent. Sutent also cut the risk of dying by 60%, says Eric Raymond, MD, head of medical oncology at the Hospital Beaujon in Clichy, France.
[…] Anti-Angiogenic Chemo May Help Fight Pancreatic Cancer […]Reply